Circulating Tumour DNA and Extracellular Vesicle-Associated DNA as Biomarkers for Cancer Detection: A Systematic Review and Meta-Analysis
Extracellular vesicle DNA offers a practical alternative to current blood tests for detecting cancer mutations, potentially expanding screening options.
This meta-analysis of 12 studies (765 patients) compared extracellular vesicle-associated DNA (EV-DNA) versus circulating tumor DNA (ctDNA) as liquid biopsy biomarkers for cancer mutation detection. EV-DNA demonstrated slightly lower sensitivity but comparable specificity to ctDNA, supporting its role as a complementary rather than competing detection tool.
What the study was
- Study design
- Systematic review and meta-analysis (12 studies, n=765 patients)
- Population
- Cancer patients across multiple tumor types
- Sample size
- 765
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Journal of extracellular biology
Why it surfaced
Systematic review and meta-analysis comparing two liquid biopsy technologies for cancer detection; PMC full text available; EARLY_CANCER_DETECTION flag elevates to HIGH.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.